Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TOLVAPTAN

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Jinarc · DIN 02491575 · 15mg & 15mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jinarc · DIN 02491575 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2025-07-31 Health Canada: Marketed since 2020-03-26 · brand JINARC · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 15 MG, TOLVAPTAN 15 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Check this DIN again · Health Canada product record

Jinarc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98156 · Verify on the e-Formulary ↗ (DIN 02491575)

Source record
DIN 02491575: Jinarc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800057; group id 568; item number 1514; lccId None; manufacturer id OTS Source form: 14-Tabs Pk; strength: 15mg & 15mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491575 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98156
Interchangeable products
Lupin-Tolvaptan · DIN 02557177 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02491575
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Tolvaptan · DIN 02557177 · 15mg & 15mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Tolvaptan · DIN 02557177 Manufacturer: Lupin Pharma Canada Limited; listing date 2025-07-31 Health Canada: Marketed since 2026-01-21 · brand LUPIN-TOLVAPTAN · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 15 MG, TOLVAPTAN 15 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106052 · Verify on the e-Formulary ↗ (DIN 02557177)

Source record
DIN 02557177: Lupin-Tolvaptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800057; group id 568; item number 1514; lccId None; manufacturer id LUP Source form: 14-Tabs Pk; strength: 15mg & 15mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $863.8125; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02557177 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106052
Interchangeable products
Jinarc · DIN 02491575 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02557177
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jinarc · DIN 02491583 · 30mg & 15mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jinarc · DIN 02491583 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2025-07-31 Health Canada: Marketed since 2020-03-26 · brand JINARC · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 15 MG, TOLVAPTAN 30 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Check this DIN again · Health Canada product record

Jinarc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98157 · Verify on the e-Formulary ↗ (DIN 02491583)

Source record
DIN 02491583: Jinarc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800058; group id 568; item number 1515; lccId None; manufacturer id OTS Source form: 14-Tabs Pk; strength: 30mg & 15mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491583 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98157
Interchangeable products
Lupin-Tolvaptan · DIN 02557185 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02491583
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Tolvaptan · DIN 02557185 · 30mg & 15mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Tolvaptan · DIN 02557185 Manufacturer: Lupin Pharma Canada Limited; listing date 2025-07-31 Health Canada: Marketed since 2026-01-21 · brand LUPIN-TOLVAPTAN · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 15 MG, TOLVAPTAN 30 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106053 · Verify on the e-Formulary ↗ (DIN 02557185)

Source record
DIN 02557185: Lupin-Tolvaptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800058; group id 568; item number 1515; lccId None; manufacturer id LUP Source form: 14-Tabs Pk; strength: 30mg & 15mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $863.8125; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02557185 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106053
Interchangeable products
Jinarc · DIN 02491583 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02557185
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jinarc · DIN 02437503 · 45mg & 15mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jinarc · DIN 02437503 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2025-07-31 Health Canada: Marketed since 2015-06-01 · brand JINARC · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 15 MG, TOLVAPTAN 45 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Check this DIN again · Health Canada product record

Jinarc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92184 · Verify on the e-Formulary ↗ (DIN 02437503)

Source record
DIN 02437503: Jinarc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800059; group id 568; item number 1516; lccId None; manufacturer id OTS Source form: 14-Tabs Pk; strength: 45mg & 15mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437503 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92184
Interchangeable products
Lupin-Tolvaptan · DIN 02557193 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437503
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Tolvaptan · DIN 02557193 · 45mg & 15mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Tolvaptan · DIN 02557193 Manufacturer: Lupin Pharma Canada Limited; listing date 2025-07-31 Health Canada: Marketed since 2026-01-21 · brand LUPIN-TOLVAPTAN · ATC not recorded · form Tablet · route Oral · ingredients TOLVAPTAN 15 MG, TOLVAPTAN 45 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106054 · Verify on the e-Formulary ↗ (DIN 02557193)

Source record
DIN 02557193: Lupin-Tolvaptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800059; group id 568; item number 1516; lccId None; manufacturer id LUP Source form: 14-Tabs Pk; strength: 45mg & 15mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $863.8125; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02557193 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106054
Interchangeable products
Jinarc · DIN 02437503 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02557193
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jinarc · DIN 02437511 · 60mg & 30mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jinarc · DIN 02437511 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2025-07-31 Health Canada: Marketed since 2015-06-01 · brand JINARC · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 30 MG, TOLVAPTAN 60 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Check this DIN again · Health Canada product record

Jinarc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92185 · Verify on the e-Formulary ↗ (DIN 02437511)

Source record
DIN 02437511: Jinarc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800060; group id 568; item number 1517; lccId None; manufacturer id OTS Source form: 14-Tabs Pk; strength: 60mg & 30mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437511 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92185
Interchangeable products
Lupin-Tolvaptan · DIN 02557207 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437511
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Tolvaptan · DIN 02557207 · 60mg & 30mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Tolvaptan · DIN 02557207 Manufacturer: Lupin Pharma Canada Limited; listing date 2025-07-31 Health Canada: Marketed since 2026-01-21 · brand LUPIN-TOLVAPTAN · ATC not recorded · form Tablet · route Oral · ingredients TOLVAPTAN 60 MG, TOLVAPTAN 30 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106055 · Verify on the e-Formulary ↗ (DIN 02557207)

Source record
DIN 02557207: Lupin-Tolvaptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800060; group id 568; item number 1517; lccId None; manufacturer id LUP Source form: 14-Tabs Pk; strength: 60mg & 30mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $864.0000; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02557207 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106055
Interchangeable products
Jinarc · DIN 02437511 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02557207
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jinarc · DIN 02437538 · 90mg & 30mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jinarc · DIN 02437538 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2025-07-31 Health Canada: Marketed since 2015-06-01 · brand JINARC · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 90 MG, TOLVAPTAN 30 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Check this DIN again · Health Canada product record

Jinarc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92186 · Verify on the e-Formulary ↗ (DIN 02437538)

Source record
DIN 02437538: Jinarc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800061; group id 568; item number 1518; lccId None; manufacturer id OTS Source form: 14-Tabs Pk; strength: 90mg & 30mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437538 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92186
Interchangeable products
Lupin-Tolvaptan · DIN 02557215 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437538
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Tolvaptan · DIN 02557215 · 90mg & 30mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Tolvaptan · DIN 02557215 Manufacturer: Lupin Pharma Canada Limited; listing date 2025-07-31 Health Canada: Marketed since 2026-01-21 · brand LUPIN-TOLVAPTAN · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 30 MG, TOLVAPTAN 90 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106056 · Verify on the e-Formulary ↗ (DIN 02557215)

Source record
DIN 02557215: Lupin-Tolvaptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800061; group id 568; item number 1518; lccId None; manufacturer id LUP Source form: 14-Tabs Pk; strength: 90mg & 30mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $864.0000; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02557215 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106056
Interchangeable products
Jinarc · DIN 02437538 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02557215
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications JINARC (tolvaptan) is indicated: • To slow the progression of kidney enlargement and kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD). In ADPKD, kidney enlargement reflects renal cyst burden. In order to select patients who might best benefit from the effects of JINARC, clinical trials evaluated ADPKD patients having a total kidney volume (TKV) ≥ 750 mL, and/or renal function corresponding to a CKD-EPI eGFR ≥25 mL/min/1.73m2, at the time of initiation of treatment. JINARC treatment should be initiated and monitored under the supervision of a nephrologist or specialist physician with expertise in the management of patients with ADPKD and a full understanding of the benefits and risks of tolvaptan therapy including hepatic toxicity and monitoring requirements. Careful consideration and discussion of the appropriateness of JINARC treatment should be undertaken between the prescriber and patient before initiation of therapy, taking into account the potential benefits and risks of treatment. Upon mutual agreement to undertake treatment with JINARC, a signed, duly-documented, manufacturer and product-specific patient-p… https://pdf.hres.ca/dpd_pm/00085722.PDF PM date: 2026-08-12 Source product: JINARC; DIN 02437503; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Jinarc, Lupin-Tolvaptan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026